Selective and potent VEGFR 1, 2, 3 inhibitor with a long half-life1*
FOTIVDA is a potent and selective triple VEGFR inhibitor with a long half-life1*
In this video, Dr. Barata discusses why VEGFR inhibition is important in treating patients with advanced RCC.
Highly vascular tumors in clear cell rrRCC demand VEGFR inhibition2
- Less selective VEGFR TKIs inhibit a range of other kinases3
VEGFR 1, 2, 3 enables1:
- Angiogenesis
- Tumor growth
- Progression
Tivozanib inhibits1*:
- Phosphorylation of VEGFR 1, 2, 3
Leading to a reduction in1‡:
- Angiogenesis
- Vascular permeability
- Tumor growth
*In vitro.1
†In human RCC in tumor xenograft models.1
Watch Dr. Barata, Director of GU Oncology Research at University Seidman Cancer Center, talk about FOTIVDA and its targeted mechanism of action.
Explore the importance of VEGFR in previously treated patients.
Reach out to an AVEO Oncology Account Manager.
RCC=renal cell carcinoma; rrRCC=relapsed/refractory renal cell carcinoma; TKI=tyrosine kinase inhibitor; VEGFR=vascular endothelial growth factor receptor.
References: 1. FOTIVDA (tivozanib) [package insert]. Boston, MA: AVEO Pharmaceuticals, Inc, August 2024. 2. Makhov P, Joshi S, Kutikov A, et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17(7):1355-1364. 3. Albiges L, Barthelemy P, Gross-Goupil M, Negrier S, Needle MN, Escudier B. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Annals Oncol. 2021;32(1):97-102.